CoChat
Sign Up
Cited by 962

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

Chan, Raymond H., Maron, Barry J., Olivotto, Iacopo, Pencina, Michael J., Assenza, Gabriele Egidy, Haas, Tammy, Lesser, John R., Gruner, Christiane, Crean, Andrew M., Rakowski, Harry, Udelson, James E., Rowin, Ethan, Lombardi, Massimo, Cecchi, Franco, Tomberli, Benedetta, Spirito, Paolo, Formisano, Francesco, Biagini, Elena, Rapezzi, Claudio, De Cecco, Carlo Nicola, Autore, Camillo, Cook, E. Francis, Hong, Susie N., Gibson, C. Michael, Manning, Warren J., Appelbaum, Evan, Maron, Martin S.·2014·Circulation
DOI 10.1161/circulationaha.113.007094
Open this paper in CoChat — free account

Abstract

Background—: Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden death in the young, although not all patients eligible for sudden death prevention with an implantable cardioverter-defibrillator are identified. Contrast-enhanced cardiovascular magnetic resonance with late gadolinium enhancement (LGE) has emerged as an in vivo marker of myocardial fibrosis, although its role in stratifying sudden death risk in subgroups of HCM patients remains incompletely understood. Methods and Results—: We assessed the relation between LGE and cardiovascular outcomes in 1293 HCM patients referred for cardiovascular magnetic resonance and followed up for a median of 3.3 years. Sudden cardiac death (SCD) events (including appropriate defibrillator interventions) occurred in 37 patients (3%). A continuous relationship was evident between LGE by percent left ventricular mass and SCD event risk in HCM patients ( P =0.001). Extent of LGE was associated with an increased risk of SCD events (adjusted hazard ratio, 1.46/10% increase in LGE; P =0.002), even after adjustment for other relevant disease variables. LGE of ≥15% of LV mass demonstrated a 2-fold increase in SCD event risk in those patients otherwise considered to be at lower risk, with an estimated likelihood for SCD events of 6% at 5 years. Performance of the SCD event risk model was enhanced by LGE (net reclassification index, 12.9%; 95% confidence interval, 0.3–38.3). Absence of LGE was associated with lower risk for SCD events (adjusted hazard ratio, 0.39; P =0.02). Extent of LGE also predicted the development of end-stage HCM with systolic dysfunction (adjusted hazard ratio, 1.80/10% increase in LGE; P <0.03). Conclusions—: Extensive LGE measured by quantitative contrast enhanced CMR provides additional information for assessing SCD event risk among HCM patients, particularly patients otherwise judged to be at low risk.

Overview

Integrity signals

Registry

Crossref · 10.1161/circulationaha.113.007094

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Extensive fibrosis (typical threshold ≥15%), detected by late gadolinium enhancement, doubles the risk of sudden cardiac death in patients with no other risk factors, with an estimated risk for life threatening arrhythmia of 6% at five years.

    “Extensive fibrosis (typical threshold ≥15%), detected by late gadolinium enhancement, doubles the risk of sudden cardiac death in patients with no other risk factors, with an estimated risk for life threatening arrhythmia of 6% at five years.”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [107]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. 10.1136/hrt.20.1.1 · DOI
  2. 10.1016/S0735-1097(03)00941-0 · DOI
  3. 10.1161/circulationaha.109.878579 · DOI
  4. 10.1016/j.jacc.2011.06.011 · DOI · Paper page
  5. 10.1016/S0735-1097(00)01003-2 · DOI
  6. 10.1016/S0140-6736(12)60397-3 · DOI · Paper page
  7. 10.1001/jama.298.4.405 · DOI
  8. 10.1016/j.amjcard.2007.09.101 · DOI
  9. 10.1161/CIRCIMAGING.108.824839 · DOI
  10. 10.1056/NEJM200002103420601 · DOI · Paper page
  11. 10.1016/j.amjcard.2004.01.057 · DOI
  12. 10.1016/j.jacc.2013.01.037 · DOI
  13. 10.1016/S0735-1097(03)00827-1 · DOI · Paper page
  14. 10.1016/S0735-1097(99)00492-1 · DOI
  15. 10.1053/hupa.2000.16659 · DOI
  16. 10.1161/circulationaha.108.811547 · DOI
  17. 10.1007/s11886-006-0010-5 · DOI
  18. Moon JC, McKenna WJ. The emerging role of cardiovascular magnetic resonance in refining the diagnosis of hypertrophic cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2009;6:166–167.
  19. 10.1007/s11886-009-0010-3 · DOI
  20. 10.1016/j.jacc.2004.03.035 · DOI
  21. 10.1016/S0735-1097(03)00190-6 · DOI
  22. 10.1016/j.jacc.2009.04.026 · DOI
  23. 10.1093/eurheartj/ehi518 · DOI
  24. 10.1007/s10554-008-9292-6 · DOI
  25. 10.1186/1532-429X-12-30 · DOI
  26. 10.1016/j.amjcard.2009.09.045 · DOI
  27. 10.1016/j.jacc.2010.06.004 · DOI
  28. 10.1186/1532-429X-14-13 · DOI
  29. 10.1161/circheartfailure.108.768119 · DOI
  30. 10.1136/bmjopen-2012-001267 · DOI
  31. 10.1161/01.CIR.102.8.858 · DOI · Paper page
  32. 10.1161/circulationaha.105.583500 · DOI
  33. 10.1161/hc0402.102975 · DOI
  34. 10.1148/radiol.10090526 · DOI
  35. 10.1016/j.jcmg.2012.10.028 · DOI
  36. 10.1016/j.jcmg.2012.09.018 · DOI
  37. 10.1093/aje/kws207 · DOI · Paper page
  38. 10.1002/sim.2929 · DOI · Paper page
  39. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 · DOI
  40. 10.1016/j.jacc.2009.05.006 · DOI
  41. 10.1016/j.jacc.2010.05.010 · DOI
  42. 10.1016/j.jacc.2010.05.007 · DOI
  43. 10.1161/circheartfailure.109.854026 · DOI
  44. 10.1016/j.jcmg.2011.11.021 · DOI
  45. 10.1016/S0735-1097(03)00189-X · DOI
  46. 10.1016/S0735-1097(02)02602-5 · DOI
  47. 10.1161/circulationaha.105.580381 · DOI
  48. 10.1016/j.jacc.2010.11.013 · DOI
  49. 10.1016/j.amjcard.2010.03.020 · DOI
  50. 10.1016/j.jacc.2008.05.058 · DOI

Cited by

Sorted by citations

Metadata

Authors
Chan, R. H., Maron, B. J., Olivotto, I., Pencina, M. J., Assenza, G. E., Haas, T., Lesser, J. R., Gruner, C., Crean, A. M., Rakowski, H., Udelson, J. E., Rowin, E., Lombardi, M., Cecchi, F., Tomberli, B., Spirito, P., Formisano, F., Biagini, E., Rapezzi, C., De Cecco, C. N., Autore, C., Cook, E. F., Hong, S. N., Gibson, C. M., Manning, W. J., Appelbaum, E., & Maron, M. S.
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2014-08-05
Volume
130
Issue
6
Pages
484-495
ISSN
  • 0009-7322
  • 1524-4539
DOI
10.1161/circulationaha.113.007094
Cited by
962
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review